

Sigurdur Yngvi Kristinsson

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4772405/publications.pdf>

Version: 2024-02-01

142
papers

10,944
citations

36271

51
h-index

31818

101
g-index

143
all docs

143
docs citations

143
times ranked

11473
citing authors

#	ARTICLE	IF	CITATIONS
1	International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. <i>Lancet Oncology</i> , The, 2014, 15, e538-e548.	5.1	3,343
2	Multiple myeloma and infections: a population-based study on 9253 multiple myeloma patients. <i>Haematologica</i> , 2015, 100, 107-113.	1.7	356
3	Racial disparities in incidence and outcome in multiple myeloma: a population-based study. <i>Blood</i> , 2010, 116, 5501-5506.	0.6	308
4	Patterns of Survival in Multiple Myeloma: A Population-Based Study of Patients Diagnosed in Sweden From 1973 to 2003. <i>Journal of Clinical Oncology</i> , 2007, 25, 1993-1999.	0.8	275
5	Long-term risks after splenectomy among 8,149 cancer-free American veterans: a cohort study with up to 27 years follow-up. <i>Haematologica</i> , 2014, 99, 392-398.	1.7	249
6	Chronic Immune Stimulation Might Act As a Trigger for the Development of Acute Myeloid Leukemia or Myelodysplastic Syndromes. <i>Journal of Clinical Oncology</i> , 2011, 29, 2897-2903.	0.8	239
7	Increased risks of polycythemia vera, essential thrombocythemia, and myelofibrosis among 24%577 first-degree relatives of 11%039 patients with myeloproliferative neoplasms in Sweden. <i>Blood</i> , 2008, 112, 2199-2204.	0.6	226
8	Treatment-Related Risk Factors for Transformation to Acute Myeloid Leukemia and Myelodysplastic Syndromes in Myeloproliferative Neoplasms. <i>Journal of Clinical Oncology</i> , 2011, 29, 2410-2415.	0.8	215
9	Arterial and venous thrombosis in monoclonal gammopathy of undetermined significance and multiple myeloma: a population-based study. <i>Blood</i> , 2010, 115, 4991-4998.	0.6	204
10	Success Story of Targeted Therapy in Chronic Myeloid Leukemia: A Population-Based Study of Patients Diagnosed in Sweden From 1973 to 2008. <i>Journal of Clinical Oncology</i> , 2011, 29, 2514-2520.	0.8	183
11	Patterns of Survival Among Patients With Myeloproliferative Neoplasms Diagnosed in Sweden From 1973 to 2008: A Population-Based Study. <i>Journal of Clinical Oncology</i> , 2012, 30, 2995-3001.	0.8	182
12	Risk for Arterial and Venous Thrombosis in Patients With Myeloproliferative Neoplasms. <i>Annals of Internal Medicine</i> , 2018, 168, 317.	2.0	177
13	Risk of acute myeloid leukemia and myelodysplastic syndromes after multiple myeloma and its precursor disease (MGUS). <i>Blood</i> , 2011, 118, 4086-4092.	0.6	173
14	Deep vein thrombosis after monoclonal gammopathy of undetermined significance and multiple myeloma. <i>Blood</i> , 2008, 112, 3582-3586.	0.6	170
15	Patterns of Improved Survival in Patients With Multiple Myeloma in the Twenty-First Century: A Population-Based Study. <i>Journal of Clinical Oncology</i> , 2010, 28, 830-834.	0.8	165
16	Monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM): novel biological insights and development of early treatment strategies. <i>Blood</i> , 2011, 117, 5573-5581.	0.6	161
17	Autoimmunity and the risk of myeloproliferative neoplasms. <i>Haematologica</i> , 2010, 95, 1216-1220.	1.7	151
18	Genome-wide association study identifies multiple susceptibility loci for multiple myeloma. <i>Nature Communications</i> , 2016, 7, 12050.	5.8	146

#	ARTICLE	IF	CITATIONS
19	Risk of lymphoproliferative disorders among first-degree relatives of lymphoplasmacytic lymphoma/Waldenström macroglobulinemia patients: a population-based study in Sweden. <i>Blood</i> , 2008, 112, 3052-3056.	0.6	143
20	Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group. <i>Lancet Oncology</i> , The, 2021, 22, e105-e118.	5.1	136
21	Risk of plasma cell and lymphoproliferative disorders among 14621 first-degree relatives of 4458 patients with monoclonal gammopathy of undetermined significance in Sweden. <i>Blood</i> , 2009, 114, 791-795.	0.6	133
22	Elevated risk of chronic lymphocytic leukemia and other indolent non-Hodgkin's lymphomas among relatives of patients with chronic lymphocytic leukemia. <i>Haematologica</i> , 2009, 94, 647-653.	1.7	113
23	Patterns of Multiple Myeloma During the Past 5 Decades: Stable Incidence Rates for All Age Groups in the Population but Rapidly Changing Age Distribution in the Clinic. <i>Mayo Clinic Proceedings</i> , 2010, 85, 225-230.	1.4	113
24	Monoclonal gammopathy of undetermined significance and risk of infections: a population-based study. <i>Haematologica</i> , 2012, 97, 854-858.	1.7	110
25	Second malignancies after multiple myeloma: from 1960s to 2010s. <i>Blood</i> , 2012, 119, 2731-2737.	0.6	108
26	Risk and Cause of Death in Patients Diagnosed With Myeloproliferative Neoplasms in Sweden Between 1973 and 2005: A Population-Based Study. <i>Journal of Clinical Oncology</i> , 2015, 33, 2288-2295.	0.8	106
27	Monoclonal gammopathy of undetermined significance and risk of lymphoid and myeloid malignancies: 728 cases followed up to 30 years in Sweden. <i>Blood</i> , 2014, 123, 338-345.	0.6	105
28	Ascertainment and diagnostic accuracy for hematopoietic lymphoproliferative malignancies in Sweden 1964–2003. <i>International Journal of Cancer</i> , 2007, 121, 2260-2266.	2.3	104
29	Improved patient survival for acute myeloid leukemia: a population-based study of 9729 patients diagnosed in Sweden between 1973 and 2005. <i>Blood</i> , 2009, 113, 3666-3672.	0.6	103
30	Outcome and survival of myeloma patients diagnosed 2008–2015. Real-world data on 4904 patients from the Swedish Myeloma Registry. <i>Haematologica</i> , 2018, 103, 506-513.	1.7	103
31	Variants in ELL2 influencing immunoglobulin levels associate with multiple myeloma. <i>Nature Communications</i> , 2015, 6, 7213.	5.8	101
32	Cancer Risk Among Patients With Myotonic Muscular Dystrophy. <i>JAMA - Journal of the American Medical Association</i> , 2011, 306, 2480-6.	3.8	99
33	Patterns of survival and causes of death following a diagnosis of monoclonal gammopathy of undetermined significance: a population-based study. <i>Haematologica</i> , 2009, 94, 1714-1720.	1.7	95
34	The Role of Diagnosis and Clinical Follow-up of Monoclonal Gammopathy of Undetermined Significance on Survival in Multiple Myeloma. <i>JAMA Oncology</i> , 2015, 1, 168.	3.4	93
35	Monoclonal gammopathy of undetermined significance and risk of skeletal fractures: a population-based study. <i>Blood</i> , 2010, 116, 2651-2655.	0.6	89
36	Thrombosis in Multiple Myeloma. <i>Hematology American Society of Hematology Education Program</i> , 2010, 2010, 437-444.	0.9	89

#	ARTICLE	IF	CITATIONS
37	Dramatically improved survival in multiple myeloma patients in the recent decade: results from a Swedish population-based study. <i>Haematologica</i> , 2018, 103, e412-e415.	1.7	87
38	Identification of multiple risk loci and regulatory mechanisms influencing susceptibility to multiple myeloma. <i>Nature Communications</i> , 2018, 9, 3707.	5.8	86
39	Highly increased familial risks for specific lymphoma subtypes. <i>British Journal of Haematology</i> , 2009, 146, 91-94.	1.2	85
40	Immune-Related and Inflammatory Conditions and Risk of Lymphoplasmacytic Lymphoma or Waldenström Macroglobulinemia. <i>Journal of the National Cancer Institute</i> , 2010, 102, 557-567.	3.0	83
41	Increased Risk for Non-Hodgkin Lymphoma in Individuals With Celiac Disease and a Potential Familial Association. <i>Gastroenterology</i> , 2009, 136, 91-98.	0.6	78
42	Personal and family history of immune-related conditions increase the risk of plasma cell disorders: a population-based study. <i>Blood</i> , 2011, 118, 6284-6291.	0.6	74
43	Improved survival in chronic lymphocytic leukemia in the past decade: a population-based study including 11,179 patients diagnosed between 1973-2003 in Sweden. <i>Haematologica</i> , 2009, 94, 1259-1265.	1.7	72
44	Progress in Hodgkin lymphoma: a population-based study on patients diagnosed in Sweden from 1973-2009. <i>Blood</i> , 2012, 119, 990-996.	0.6	69
45	Thrombosis is associated with inferior survival in multiple myeloma. <i>Haematologica</i> , 2012, 97, 1603-1607.	1.7	66
46	Patterns of survival in lymphoplasmacytic lymphoma/waldenström macroglobulinemia: A population-based study of 1,555 patients diagnosed in Sweden from 1980 to 2005. <i>American Journal of Hematology</i> , 2013, 88, 60-65.	2.0	66
47	Second malignancies in patients with myeloproliferative neoplasms: a population-based cohort study of 9379 patients. <i>Leukemia</i> , 2018, 32, 2203-2210.	3.3	64
48	Patterns of hematologic malignancies and solid tumors among 37,838 first-degree relatives of 13,896 patients with multiple myeloma in Sweden. <i>International Journal of Cancer</i> , 2009, 125, 2147-2150.	2.3	63
49	Socioeconomic Differences in Patient Survival Are Increasing for Acute Myeloid Leukemia and Multiple Myeloma in Sweden. <i>Journal of Clinical Oncology</i> , 2009, 27, 2073-2080.	0.8	59
50	A population-based assessment of mortality and morbidity patterns among patients with thymoma. <i>International Journal of Cancer</i> , 2011, 128, 2688-2694.	2.3	59
51	Association of Immune Marker Changes With Progression of Monoclonal Gammopathy of Undetermined Significance to Multiple Myeloma. <i>JAMA Oncology</i> , 2019, 5, 1293.	3.4	57
52	Iceland screens, treats, or prevents multiple myeloma (iStopMM): a population-based screening study for monoclonal gammopathy of undetermined significance and randomized controlled trial of follow-up strategies. <i>Blood Cancer Journal</i> , 2021, 11, 94.	2.8	52
53	Incidence, characteristics, and outcome of solitary plasmacytoma and plasma cell leukemia. Population-based data from the Swedish Myeloma Register. <i>European Journal of Haematology</i> , 2017, 99, 216-222.	1.1	48
54	Obesity and risk of monoclonal gammopathy of undetermined significance and progression to multiple myeloma: a population-based study. <i>Blood Advances</i> , 2017, 1, 2186-2192.	2.5	47

#	ARTICLE	IF	CITATIONS
55	Bone disease in multiple myeloma and precursor disease: novel diagnostic approaches and implications on clinical management. <i>Expert Review of Molecular Diagnostics</i> , 2011, 11, 593-603.	1.5	35
56	Familial Aggregation of Acute Myeloid Leukemia and Myelodysplastic Syndromes. <i>Journal of Clinical Oncology</i> , 2012, 30, 179-183.	0.8	35
57	Incidence of multiple myeloma in Great Britain, Sweden, and Malmö, Sweden: the impact of differences in case ascertainment on observed incidence trends. <i>BMJ Open</i> , 2016, 6, e009584.	0.8	32
58	Genetic and immune-related factors in the pathogenesis of lymphoproliferative and plasma cell malignancies. <i>Haematologica</i> , 2009, 94, 1581-1589.	1.7	30
59	Fractures and survival in multiple myeloma: results from a population-based study. <i>Haematologica</i> , 2020, 105, 1067-1073.	1.7	29
60	Autoimmunity and risk for Hodgkin's lymphoma by subtype. <i>Haematologica</i> , 2009, 94, 1468-1469.	1.7	28
61	Survival in multiple myeloma patients who develop second malignancies: a population-based cohort study. <i>Haematologica</i> , 2016, 101, e145-e148.	1.7	26
62	Pregnancy and the Risk of Relapse in Patients Diagnosed With Hodgkin Lymphoma. <i>Journal of Clinical Oncology</i> , 2016, 34, 337-344.	0.8	26
63	Novel Aspects Pertaining to the Relationship of Waldenström's Macroglobulinemia, IgM Monoclonal Gammopathy of Undetermined Significance, Polyclonal Gammopathy, and Hypoglobulinemia. <i>Clinical Lymphoma and Myeloma</i> , 2009, 9, 19-22.	1.4	25
64	Bone disease in monoclonal gammopathy of undetermined significance: results from a screened population-based study. <i>Blood Advances</i> , 2017, 1, 2790-2798.	2.5	23
65	Quantifying Cancer Absolute Risk and Cancer Mortality in the Presence of Competing Events after a Myotonic Dystrophy Diagnosis. <i>PLoS ONE</i> , 2013, 8, e79851.	1.1	23
66	No familial aggregation in chronic myeloid leukemia. <i>Blood</i> , 2013, 122, 460-461.	0.6	22
67	Timing of births and endometrial cancer risk in Swedish women. <i>Cancer Causes and Control</i> , 2009, 20, 1441-1449.	0.8	21
68	Prior history of non-melanoma skin cancer is associated with increased mortality in patients with chronic lymphocytic leukemia. <i>Haematologica</i> , 2009, 94, 1460-1464.	1.7	21
69	Population-based study on the impact of the familial form of Waldenström macroglobulinemia on overall survival. <i>Blood</i> , 2015, 125, 2174-2175.	0.6	21
70	Temporal trends in the proportion cured among adults diagnosed with acute myeloid leukaemia in Sweden 1973-2001, a population-based study. <i>British Journal of Haematology</i> , 2010, 148, 918-924.	1.2	20
71	History of autoimmune disease is associated with impaired survival in multiple myeloma and monoclonal gammopathy of undetermined significance: a population-based study. <i>Annals of Hematology</i> , 2017, 96, 261-269.	0.8	20
72	Familial Aggregation of Lymphoplasmacytic Lymphoma/Waldenström Macroglobulinemia with Solid Tumors and Myeloid Malignancies. <i>Acta Haematologica</i> , 2012, 127, 173-177.	0.7	19

#	ARTICLE	IF	CITATIONS
73	Dietary intake is associated with risk of multiple myeloma and its precursor disease. PLoS ONE, 2018, 13, e0206047.	1.1	19
74	Comorbidities in multiple myeloma and implications on survival: A population-based study. European Journal of Haematology, 2021, 106, 774-782.	1.1	18
75	Genetics- and Immune-Related Factors in the Pathogenesis of Lymphoplasmacytic Lymphoma/Waldenström's Macroglobulinemia. Clinical Lymphoma and Myeloma, 2009, 9, 23-26.	1.4	16
76	Incidence and risk factors for suicide and attempted suicide following a diagnosis of hematological malignancy. Cancer Medicine, 2015, 4, 147-154.	1.3	16
77	The impact of prior malignancies on second malignancies and survival in MM patients: a population-based study. Blood Advances, 2017, 1, 2392-2398.	2.5	15
78	Risk of solid tumors and myeloid hematological malignancies among first-degree relatives of patients with monoclonal gammopathy of undetermined significance. Haematologica, 2009, 94, 1179-1181.	1.7	14
79	Survival Patterns in Patients With Hodgkin's Lymphoma With a Pre-Existing Hospital Discharge Diagnosis of Autoimmune Disease. Journal of Clinical Oncology, 2010, 28, 5081-5087.	0.8	14
80	Borrelia and subsequent risk of solid tumors and hematologic malignancies in Sweden. International Journal of Cancer, 2012, 131, 2208-2209.	2.3	14
81	Hemoglobin concentration and risk of arterial and venous thrombosis in 1.5 million Swedish and Danish blood donors. Thrombosis Research, 2020, 186, 86-92.	0.8	14
82	Hypercoagulability in Multiple Myeloma and Its Precursor State, Monoclonal Gammopathy of Undetermined Significance. Seminars in Hematology, 2011, 48, 46-54.	1.8	13
83	Bloodstream infections in patients with chronic lymphocytic leukemia: a longitudinal single-center study. Annals of Hematology, 2016, 95, 871-879.	0.8	13
84	Bone Marrow Fibrosis In Patients With Multiple Myeloma: A New Prognostic Factor For Survival?. Blood, 2013, 122, 1946-1946.	0.6	13
85	Risk for Arterial and Venous Thrombosis in Patients With Myeloproliferative Neoplasms. Annals of Internal Medicine, 2018, 169, 268.	2.0	12
86	Peripheral neuropathy and monoclonal gammopathy of undetermined significance: a population-based study including 15,351 cases and 58,619 matched controls. Haematologica, 2020, 105, 2679-2681.	1.7	11
87	Epidemiology of hairy cell leukemia in Iceland. The Hematology Journal, 2002, 3, 145-147.	2.0	11
88	Risk of Arterial and Venous Thrombosis in 11,155 Patients with Myeloproliferative Neoplasms and 44,620 Matched Controls; A Population-Based Study. Blood, 2014, 124, 632-632.	0.6	11
89	What Causes Waldenström's Macroglobulinemia: Genetic or Immune-Related Factors, or a Combination?. Clinical Lymphoma, Myeloma and Leukemia, 2011, 11, 85-87.	0.2	10
90	Etiology of Waldenström Macroglobulinemia: Genetic Factors and Immune-related Conditions. Clinical Lymphoma, Myeloma and Leukemia, 2013, 13, 194-197.	0.2	10

#	ARTICLE	IF	CITATIONS
91	Hodgkin lymphoma risk following infectious and chronic inflammatory diseases: a large population-based caseâ€“control study from Sweden. <i>International Journal of Hematology</i> , 2015, 101, 563-568.	0.7	10
92	Autoimmunity, Infections, and the Risk of Monoclonal Gammopathy of Undetermined Significance. <i>Frontiers in Immunology</i> , 2022, 13, 876271.	2.2	9
93	Fatal pneumocystis jiroveci pneumonia in ABVD-treated Hodgkin lymphoma patients. <i>Annals of Hematology</i> , 2010, 89, 523-525.	0.8	8
94	Infection in infancy and subsequent risk of developing lymphoma in children and young adults. <i>Blood</i> , 2011, 117, 1670-1672.	0.6	8
95	Survival in Monoclonal Gammopathy of Undetermined Significance and Waldenstr�m Macroglobulinemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2013, 13, 187-190.	0.2	8
96	Survival in patients with familial and sporadic myeloproliferative neoplasms. <i>Blood</i> , 2015, 125, 3665-3666.	0.6	8
97	Outcome and characteristics of non�measurable myeloma: A cohort study with population�based data from the Swedish Myeloma Registry. <i>European Journal of Haematology</i> , 2020, 104, 376-382.	1.1	8
98	Cumulative exposure to melphalan chemotherapy and subsequent risk of developing acute myeloid leukemia and myelodysplastic syndromes in patients with multiple myeloma. <i>European Journal of Haematology</i> , 2021, 107, 275-282.	1.1	8
99	Germline and somatic JAK2 mutations and susceptibility to chronic myeloproliferative neoplasms. <i>Genome Medicine</i> , 2009, 1, 55.	3.6	7
100	Genetic variants associated with platelet count are predictive of human disease and physiological markers. <i>Communications Biology</i> , 2021, 4, 1132.	2.0	7
101	Monoclonal gammopathy of undetermined significance and COVID-19: a population-based cohort study. <i>Blood Cancer Journal</i> , 2021, 11, 191.	2.8	7
102	Illness severity and risk of mental morbidities among patients recovering from COVID-19: a cross-sectional study in the Icelandic population. <i>BMJ Open</i> , 2021, 11, e049967.	0.8	6
103	Autoimmune disease is associated with a lower risk of progression in monoclonal gammopathy of undetermined significance. <i>European Journal of Haematology</i> , 2021, 106, 380-388.	1.1	6
104	A nationwide study on inpatient opportunistic infections in patients with chronic lymphocytic leukemia in the pre�brutinib era. <i>European Journal of Haematology</i> , 2021, 106, 346-353.	1.1	5
105	Thromboprophylaxis in multiple myeloma: is the evidence there?. <i>Expert Review of Anticancer Therapy</i> , 2012, 12, 291-294.	1.1	4
106	Diabetes mellitus and risk of plasma cell and lymphoproliferative disorders in 94,579 cases and 368,348 matched controls. <i>Haematologica</i> , 2022, 107, 284-286.	1.7	4
107	Increased Risks of Polycythemia Vera (PV), Essential Thrombocythemia (ET), and Myelofibrosis (MF) among 24577 First-Degree Relatives of 11039 Patients with Chronic Myeloproliferative Disorders (MPD) in Sweden.. <i>Blood</i> , 2007, 110, 680-680.	0.6	4
108	Real World Data In Myeloma: Experiences From The Swedish Population-Based Registry On 2494 Myeloma Patients Diagnosed 2008-2011. <i>Blood</i> , 2013, 122, 1972-1972.	0.6	4

#	ARTICLE	IF	CITATIONS
109	Validity of chronic disease diagnoses in Icelandic healthcare registries. <i>Scandinavian Journal of Public Health</i> , 2021, , 140349482110599.	1.2	4
110	OUP accepted manuscript. <i>Rheumatology</i> , 2022, , .	0.9	4
111	Novel Therapies in Multiple Myeloma for Newly Diagnosed Nontransplant Candidates. <i>Cancer Journal (Sudbury, Mass)</i> , 2009, 15, 473-478.	1.0	3
112	Improved Patient Survival and Cure for Hodgkin Lymphoma: A Population-Based Study of 6,136 Patients Diagnosed in Sweden 1973-2005.. <i>Blood</i> , 2009, 114, 1553-1553.	0.6	3
113	Survival, Causes of Death, and the Prognostic Role of Comorbidities in Chronic Lymphocytic Leukemia in the preâ€brutinib era. A Population Based Study. <i>European Journal of Haematology</i> , 2021, , .	1.1	3
114	Response: More on disease anticipation in familial MPN. <i>Blood</i> , 2008, 112, 2588-2589.	0.6	2
115	A â€pilotâ€™ study on airâ€travel and venous thromboembolism. <i>British Journal of Haematology</i> , 2009, 146, 457-459.	1.2	2
116	Does Low-Molecular-Weight Heparin Influence the Antimyeloma Effects of Thalidomide? A Retrospective Analysis of Data from the GIMEMA, Nordic and Turkish Myeloma Study Groups. <i>Acta Haematologica</i> , 2015, 133, 372-380.	0.7	2
117	A populationâ€based study on serious inpatient bacterial infections in patients with chronic lymphocytic leukemia and their impact on survival. <i>European Journal of Haematology</i> , 2020, 105, 547-554.	1.1	2
118	Untangling fracture risk in monoclonal gammopathy of undetermined significance: A populationâ€based cohort study. <i>European Journal of Haematology</i> , 2021, 107, 137-144.	1.1	2
119	Arterial and Venous Thrombosis in Monoclonal Gammopathy of Undetermined Significance and Multiple Myeloma: A Population-Based Study.. <i>Blood</i> , 2009, 114, 1872-1872.	0.6	2
120	The Success Story of Targeted Therapy In Chronic Myeloid Leukemia: A Population-Based Study of 3,173 Patients Diagnosed In Sweden 1973â€2008. <i>Blood</i> , 2010, 116, 205-205.	0.6	2
121	Multiple Myeloma and Infections: A Population-Based Study Based On 9,610 Multiple Myeloma Patients. <i>Blood</i> , 2012, 120, 945-945.	0.6	2
122	The association of cancer and venous thrombosis: yes, Trousseau is right â€ again!. <i>Leukemia and Lymphoma</i> , 2011, 52, 734-735.	0.6	1
123	Epidemiology of WaldenstrÃ¶m Macroglobulinemia. , 2017, , 97-109.		1
124	Prognosis in Acute Myeloid Leukemia: A Population-Based Study on 5,809 Patients Diagnosed in Sweden 1973â€2001.. <i>Blood</i> , 2005, 106, 1845-1845.	0.6	1
125	Peripheral Neuropathy in MGUS and Progression to Amyloid Light-Chain Amyloidosis: A Population-Based Study Including 15,351 MGUS Cases. <i>Blood</i> , 2019, 134, 5444-5444.	0.6	1
126	The first wave of COVIDâ€19 and concurrent social restrictions were not associated with a negative impact on mental health and psychiatric wellâ€being. <i>Journal of Internal Medicine</i> , 2022, 291, 837-848.	2.7	1

#	ARTICLE	IF	CITATIONS
127	Re: Risk of malignancy associated with Lyme disease: Still up in the air. International Journal of Cancer, 2012, 131, 2718-2718.	2.3	0
128	Genetics in Lymphomagenesis. , 2013, , 835-847.		0
129	Immunoglobulin Type M Monoclonal Gammopathy of Undetermined Significance (IgM-MGUS). , 2017, , 143-167.		0
130	Parental longevity and survival among patients with multiple myeloma and monoclonal gammopathy of undetermined significance: a population-based study. British Journal of Haematology, 2019, 186, 37-44.	1.2	0
131	Patterns of Venous Thromboembolism (VTE) Following Monoclonal Gammopathy of Undetermined Significance (MGUS) and Multiple Myeloma (MM) among 4 Million U.S. Veterans.. Blood, 2006, 108, 4998-4998.	0.6	0
132	Increased Risk of Monoclonal Gammopathy of Undetermined Significance (MGUS) and Lymphoproliferative Tumors among 14689 First-Degree Relatives of 4488 MGUS Patients in Sweden.. Blood, 2007, 110, 660-660.	0.6	0
133	Immune-Related and Inflammatory Conditions Likely Play a Role in the Development of Lymphoplasmacytic Lymphoma/Waldenström's Macroglobulinemia. Blood, 2008, 112, 3758-3758.	0.6	0
134	Monoclonal Gammopathy of Undetermined Significance and Risk of Infections: A Population-Based Study. Blood, 2010, 116, 4053-4053.	0.6	0
135	Monoclonal Gammopathy Of Undetermined Significance and Risk Of Lymphoid and Myeloid Malignancies: 743 Cases Followed For Up To 30 Years In Sweden. Blood, 2013, 122, 3124-3124.	0.6	0
136	Multiple Myeloma Patients With Prior Knowledge Of MGUS Have a Better Survival Compared To Multiple Myeloma Patients Without Prior Knowledge Of MGUS. Blood, 2013, 122, 1984-1984.	0.6	0
137	Impact Of History Of Autoimmune Disease On Survival In Multiple Myeloma and Monoclonal Gammopathy Of Undetermined Significance: A Population-Based Study. Blood, 2013, 122, 1898-1898.	0.6	0
138	The Impact of Prior Malignancies on Second Malignancies and Survival in MM Patients: A Population-Based Study. Blood, 2016, 128, 3246-3246.	0.6	0
139	Peripheral Neuropathy Is Associated with an Increased Risk of Fractures in Individuals with Monoclonal Gammopathy of Undetermined Significance: A Population-Based Study Including 15,351 MGUS Cases. Blood, 2018, 132, 1914-1914.	0.6	0
140	The Impact of Fractures on Survival in Multiple Myeloma: Results from a Population-Based Study. Blood, 2018, 132, 4490-4490.	0.6	0
141	Monoclonal Gammopathy of Undetermined Significance and COVID-19: Results from the Population-Based Iceland Screens Treats or Prevents Multiple Myeloma Study (iStopMM). Blood, 2021, 138, 154-154.	0.6	0
142	Diabetes Mellitus and Risk of Plasma Cell and Lymphoproliferative Disorders: A Population Based Study Including 94,579 Cases and 368,348 Matched Controls. Blood, 2020, 136, 44-45.	0.6	0